$JNJ (+2.12%)
$MDLZ (+4.45%)
$HSY (+4.29%)
$NKE (-0.48%)
I sell stock portfolio waiting to go down to buy etfs dividends 🫡
Posts
311$JNJ (+2.12%)
$MDLZ (+4.45%)
$HSY (+4.29%)
$NKE (-0.48%)
I sell stock portfolio waiting to go down to buy etfs dividends 🫡
What are your favorites that you will keep for the next few years?
or do you have several 🤔
I only have Johnson and Johnson
and Merck in another portfolio
Novo Nordisk$NOVO B (+5.32%)
J&J $JNJ (+2.12%)
merck&co $MRK (+2.28%)
and all the others that exist
In the current issue, "Der Aktionär" recommends these dividend stocks.
For a peaceful night's sleep (conservative):
Top dividend with medium risk can be seen in:
Dividends with a yield kick are located in these shares:
Source: Der Aktionär, Issue 08.2025
Dear friends of Getquin,
I'm usually a silent reader, but if everyone just reads, eventually there's no more reading material, is there? So today I want to share my story with you.
The beginnings:
It's hard for me to say exactly when my journey began, but I do know that I developed a fascination with money as a child. My first "investment" was when I was about 7 or 8 years old, when I bought an ounce of gold with my own pocket money. At that time, no one in my family had anything to do with investments, but I had seen it in my mother's bank when I often accompanied her there. I was fascinated by the shiny coins and wanted to know how I could have a piece myself.
Then, around the turn of the millennium, I saw my father, together with a "great" bank advisor, invest the entire family savings in the middle of the dotcom bubble. The result: a massive loss within a few months. But my mother, who was at home at the time, fought hard and was miraculously able to recoup the losses. I was about 9 or 10 years old at the time and watched her sit in front of the PC every day and look at the figures. From that moment on, I was hooked! I started using an Excel spreadsheet to track which shares I would have bought at what price and watched the performance of my fictitious investments with great interest every day after school.
The first few years:
My mother stopped day trading after about a year and went back to work. However, shares were no longer an issue for me until I was 26.
Getting into real shares:
In 2018, in the summer, as a die-hard Juventus fan, I read about an article on the transfer of CR7 and how Juventus shares went through the roof. I was there again! At that time, however, I only had a small income as a working student. My father, who had failed with his investments in the past, gave me €2,000 - and I bought Juventus shares. However, he made me promise him that I would never invest in shares again. How did the story end? The "trade" with Juventus was a success, but I had to pay taxes for the first time - and I still hate that to this day.
The first losses:
After my Juventus adventure, I began to delve deeper into the matter. I tried out recommendations from "Aktionär" and repeatedly bet on individual shares for smaller trades. It was more of a game, but I generally remained profitable - sometimes a few percent profit, sometimes a few percent loss. Thanks to the profits and additional deposits, I built up my portfolio to €18,000 until I was hit by Wirecard. In the end, I had to accept a loss of around €6,000. It was painful, but not life-threatening - and I learned a lot from this mistake. In particular, I made the mistake of constantly buying more. If I had left it at the original position of € 1,500, the loss would probably not have been so dramatic.
Don't give up:
After the Wirecard debacle, I radically rethought my strategy. I increasingly focused on conservative companies, regular dividend payers and low growth. But here, too, I realized that I was underperforming the market. So I adapted my strategy further and took a long-term approach. I have since been able to slowly recoup my losses.
The clean cut - a new start:
In the summer of 2023, I needed all my assets for a private housing project and decided to make a real "fresh start". I sold all the positions in my portfolio and only kept my ETF savings plans with TradeRepublic.
The new era:
When the housing project was completed, I wanted to build up a new portfolio with the money I had left over - and here you can see the result. My aim is to find companies that are growing strongly and have a solid moat. Dividends are nice, but not a must. My portfolio also contains defensive, boring stocks as a healthy addition. At the same time, I try to further expand my ETF positions through one-off purchases - I stopped my regular ETF savings plans at the end of January 2025. I have also invested a little in crypto and gold on the side. I have made further investments in Lego (€500), Pokémon (€1,000) and Counterstrike cases (€3,000), but these are not part of the public list - that would be too costly for me.
Fun fact:
My cash ratio has never been higher than €3,000 since I first entered the stock market (2018). This is currently an exception because I want to build up a cash reserve for the next generation.
Goal:
I don't have a specific, set goal when it comes to my investments. It's more of a hobby for me. I just enjoy seeing how my portfolio grows and how I can accompany exciting companies and be a small part of them as they develop. For me, it feels a bit like collecting: I enjoy discovering interesting companies, investing in them and watching them develop over the long term.
Thank you:
A big thank you goes to Goldesel Investing and Markus Koch, who have been with me since my first stock market steps. Without you, the share culture in German-speaking countries would certainly not be as strong! And of course a big thank you to Getquin - I've always dreamed of a platform like this! 0% bullshit, 100% investments.
I hope you like the revised version! The text is now more clearly structured, reads more smoothly and still retains your personal style.
Please let me know if you liked my story!
A little tip: My Bitpanda portfolio has a longer history, but I was too lazy to enter everything manually. I also didn't want to take over the history because, as I said, I wanted to start a new chapter in my investment history in November 2023. Overall, however, my crypto track is up €3000-4000.
$CSPX (-1.14%)
$ETH (+1.62%)
$BLK (-1.16%)
$GS (-2.21%)
$XDWD (-0.98%)
$V (-0.16%)
$MC (+0.4%)
$MS (-1.6%)
$QCOM (-4.11%)
$JNJ (+2.12%)
$ASML (-0.72%)
$RBOT (-2.12%)
$LOCK (-1.22%)
$MRK (+2.28%)
$UNP (-0.01%)
$NKE (-0.48%)
$QDV5 (-0.66%)
$MA (-0.3%)
$TGT (-2.56%)
$PEP (+3.26%)
$NU (-11.11%)
$AAPL (+0.26%)
$TSLA (-4.32%)
$DOGE (+2.09%)
$BTC (+0.72%)
$BRK.B (-0.13%)
$PEPE (+1.86%)
Hello, I am thinking about restructuring my portfolio, which in my opinion is very unbalanced, with a view to the future. I'm thinking of an investment horizon of around 15-20 years.
I would like to structure the core of my portfolio with the help of 60% #etfs with the help of
In addition, around 5% of my postage portfolio is to be #crypto above all $BTC (+0.72%) consist of
I invest the remaining 35% in individual stocks.
I currently have a monthly savings rate of 400-500 euros in addition to my studies and would divide this up accordingly and put it into a #sparplan and put it into a savings account.
What do you think of the weighting and do you have any tips, especially in the health sector?
Brief feedback is very welcome
In the following post, I would like to discuss the new US tariffs and their potential economic consequences. The background and the potential impact on inflation and companies, as well as the winners and losers on the stock market, will be discussed.
Again, of course, the stocks mentioned do not constitute investment advice, but merely serve as examples of possible beneficiaries or losers of tightening trade restrictions. Historical developments are no guarantee of future returns.
__________
In this post:
__________
The topic of "tariffs" is currently not only very present in the media, but the term "tariffs" has also been discussed with a strong increase in the past earnings calls of companies in the S&P 500, as the following chart shows [1].
The chart shows that the discussion about tariffs has intensified in recent months and is having an ever greater impact on the outlook in companies' annual reports.
The data is presented as a three-month average and broken down into various sectors, including e.g. industry, healthcare, consumer goods, information technology, etc.
I am curious to see how the stock markets will behave in the coming week. In addition to the current reporting season, the topic of "tariffs" will certainly dominate.
After the tough tariffs announced after Trump took office were not immediately enforced and there was a "slight" sigh of relief, there could now be a new reaction on the markets, as there was on Friday evening. slightly was already slightly noticeable on Friday evening when the markets turned towards the evening.
A looming trade conflict could not only affect individual companies, but also further fuel inflation in the US:
💰 Influence on inflation
On January 31, Deutsche Bank published a forecast on the potential impact of tariffs on the inflation rate [2]:
The chart compares the current forecast with the forecast before the "Trump" era and takes into account various scenarios for the passing on of tariffs (pass-through) by Canada and Mexico.
Two scenarios are considered: one with a 50% pass-through of tariffs (additional increase shown in dark green) and one with a 75% pass-through (light green). It is clear that the inflation rate could rise sharply again this year and fall again by 2027.
🛃 New tariffs in force & further measures planned
As of today, February 1, 2025, the US government and Donald Trump have imposed new import tariffs on Mexico, Canada and China:
According to the White House spokesperson, these measures are, among other things, a response to the failure of these countries to stop the influx of fentanyl and illegal immigrants into the USA. [3]
But this is just the beginning:
From mid-February, the USA will also impose tariffs on strategic goods [4], including:
🚨 Trump relies on escalation - Canada announces retaliation
Yesterday, Canadian government representatives, including Foreign Minister Mélanie Joly, tried to prevent the tariffs in Washington, but to no avail.
Trump made it clear before his departure to Mar-a-Lago [5]:
"We have a 200 billion dollar trade deficit with Canada. Why should we subsidize Canada?"
The EU could also soon be targeted, as Trump hinted:
"Absolutely! The European Union has treated us so terribly!"
🔄 Canada's reaction:
Prime Minister Justin Trudeau announced that Canada will not back down and will respond with "swift and robust countermeasures".
The government is planning a three-stage retaliation strategy [5]:
However, this last step in particular would be a double-edged sword, as Canada is heavily dependent on energy cooperation with the USA.
Economic experts in the US are already warning of the consequences of a trade war [5]:
But Trump remains firm:
"Maybe there will be short-term disruption, but in the long run the tariffs will make us very rich and very strong."
🌎 Possible consequences for the global economy
(a) Rising prices in the USA
(b) Retaliation & new trade wars?
(c) Effects on the stock market
🏆 Winners & losers - which companies will benefit, which will suffer?
Possible beneficiaries of the tariffs
US manufacturers of steel, aluminum & copper
Domestic pharmaceutical and biotech companies
Energy companies with US production
Chip manufacturers with US production
😥 Companies that could suffer from the tariffs
Chip manufacturers with global supply chains
Car manufacturers with global suppliers
Companies with strong export business
US retailers with a high import share
🧠 Possible investment strategies
Favor defensive sectors:
Exploit long-term opportunities in "reshoring":
Conclusion: Will the trade conflict escalate further?
With the new tariffs, Trump is taking a confrontational stance and Canada, Mexico and China are preparing for retaliatory measures. If further tariffs on European goods follow, the situation could worsen.
❓Which stocks do you think could be most affected? Which beneficiaries do you see?
Thanks for reading! 🤝
__________
Sources:
[4]
[5] https://www.tagesschau.de/ausland/amerika/usa-trump-strafzoelle-100.html
Today was another rollercoaster in the financial markets as investors grappled with the aftermath of the DeepSeek AI shockwave and awaited key earnings reports from tech giants. Here’s the breakdown:
📉 **Tech Sector Volatility**: The Nasdaq clawed back some losses, gaining 1% after Monday’s steep 3.5% drop, driven by a sell-off in AI-related stocks. $NVDA (-3.63%) , the AI bellwether, rebounded 3% but remains under pressure after losing nearly $600 billion in market value earlier this week.
💡 **DeepSeek Impact**: The Chinese AI startup continues to rattle markets with its claims of building efficient AI models at a fraction of the cost. This has sparked fears of overvaluation in the U.S. tech sector, particularly for companies like $MSFT (-1.57%) and $GOOG (-2.32%) , which are heavily invested in AI infrastructure.
📈 **Defensive Plays Shine**: While tech struggled, defensive sectors like healthcare and consumer staples saw inflows. The $DOW (+0.29%) edged up 0.1%, supported by gains in $JNJ (+2.12%) and $PG (+2.23%)
🔍 **Earnings in Focus**: All eyes are on the "Magnificent Seven" this week, with $META (-1.11%) , Microsoft, $TSLA (-4.32%) , and $AAPL (+0.26%) set to report. Investors are keen to see how these companies address the AI competition and whether they can maintain their growth trajectories.
💼 **Fed Watch**: The Federal Reserve’s policy meeting tomorrow is another key event. While no rate cuts are expected, Jerome Powell’s commentary on inflation and future rate trajectories will be critical for market sentiment.
🌍 **Global Ripples**: The DeepSeek saga isn’t just a U.S. story. European and Asian markets also felt the tremors, with chipmakers like $ASML (-0.72%) and TSMC facing sell-offs. Meanwhile, oil prices dipped 2% amid concerns over global demand and tariff tensions.
🔮 **What’s Next?**: The market remains in a state of flux, balancing AI-driven growth optimism with valuation concerns. As earnings and Fed decisions unfold, expect more volatility—but also potential opportunities for savvy investors.
📌 **Key Takeaways**:
- Tech rebounds but remains fragile.
- Defensive sectors offer stability.
- Earnings and Fed decisions will set the tone.
#MarketUpdate #Investing #AI #TechStocks #FedWatch #EarningsSeason #DeepSeek #Nvidia #DefensiveStocks #Volatility
Let’s navigate these waves together! 🌊💼
Hello everyone,
Yesterday showed me once again how important it is to invest across all sectors. Anyone who invests in individual stocks should "divide" their money into as many different sectors as possible.
Tech stocks did not do so well yesterday, in contrast to some classic blue chips such as $PEP (+3.26%) or $JNJ (+2.12%) . Even if these stocks are no longer a huge growth story, they give my portfolio stability in stormy times.
So I was still able to end the day on a positive note yesterday, even though I $AVGO (-3.16%) and $KLAC (-2.61%) etc. in my portfolio.
This was probably also due to the low weighting here and there, but I'm still happy about it and feel somehow confirmed that I'm on the right track with my "strategy".
These are my current thoughts on this....how did you see yesterday?
Greetings from DivGrowth1989 ;)
🔹 Revenue: $22.52B (Est. $22.46B) 🟢; UP +5.3% YoY
🔹 Adjusted EPS: $2.04 (Est. $2.02) 🟢
🔹 Net Earnings: $3.43B; DOWN -17% YoY
FY25 Guidance:
🔹 Adj Oper. EPS: $10.75-$10.95 (Est. $10.56) 🟢
🔹 Operational Sales: $90.9B-$91.7B (Est. $90.98B) 🟢
Q4 SEGMENTS:
Innovative Medicine:
🔹 Revenue: $14.33B (Est. $14.17B) 🟢; UP +4.4% YoY
🔸 Growth driven by DARZALEX ($3.08B), ERLEADA, and CARVYKTI
🔸 Offset by declines in STELARA and other neuroscience products
MedTech:
🔹 Revenue: $8.19B (Est. $8.22B) 🟡; UP +6.7% YoY
🔸 Growth supported by electrophysiology and Abiomed in cardiovascular
🔸 Wound closure products in general surgery contributed positively
Geographic Performance:
United States:
🔹 Revenue: $13.20B; UP +10.0% YoY
International:
🔹 Revenue: $9.32B; DOWN -0.7% YoY; Operational growth +2.5% YoY
Key Metrics:
🔹 Operational Sales Growth: +6.7%
🔹 Adjusted Operational Sales Growth: +5.7%
🔹 Free Cash Flow: ~$19.8B (Prev. $18.2B)
🔹 Reported EPS: $1.41; includes $(0.22) impact from acquired IPR&D charges
FY2024 Full-Year Highlights:
🔹 Revenue: $88.8B (UP +4.3% YoY); operational growth +5.9%
🔹 Adjusted EPS: $9.98 (Prev. $9.92) 🟡
🔸 Growth driven by DARZALEX, TREMFYA, and SPRAVATO
CEO Joaquin Duato's Commentary:
🔸 "2024 was transformative, marked by strong growth, pipeline acceleration, and innovations across multiple disease areas, including oncology and immunology. Johnson & Johnson remains positioned to sustain high growth and innovation."
Pipeline and Strategic Highlights:
🔸 Progress in key areas, including RYBREVANT survival data and TAR-200 submission. 🔸 Approval of investigational device exemption for the OTTAVA robotic surgery system.
Top creators this week